Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 12/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 2/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.34 |
| ▸ | STS | P08842 | 1/20 | 0.34 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18864000 | 1.00 | PDE4B (0.39) | PDE4BUSP30PDE4APDE4CPDE4D | |
| SCHEMBL18890841 | 0.88 | USP30 (0.39) | PDE4BUSP30PDE4APDE4CPDE4D | |
| SCHEMBL14734906 | 0.83 | CHRM2 (0.41) | PDE4BPDE4APDE4CPDE4DGPR119 | |
| SCHEMBL18864074 | 0.80 | KCNK3 (0.38) | PDE4BUSP30PDE4APDE4CPDE4D | |
| SCHEMBL14735393 | 0.80 | GPR119 (0.43) | PDE4BUSP30PDE4APDE4CPDE4D | |
| SCHEMBL14735501 | 0.79 | GPR119 (0.44) | PDE4BUSP30PDE4APDE4CPDE4D | |
| SCHEMBL14735488 | 0.77 | GPR119 (0.47) | PDE4BUSP30PDE4APDE4CPDE4D | |
| SCHEMBL18890883 | 0.77 | PDE4B (0.41) | PDE4BUSP30PDE4APDE4CPDE4D | |
| SCHEMBL18864059 | 0.77 | PDE4B (0.41) | PDE4BUSP30PDE4APDE4CPDE4D | |
| SCHEMBL18890882 | 0.77 | PDE4B (0.41) | PDE4BUSP30PDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170145005-A1 | KINASE INHIBITOR | THE UNIVERSITY OF TOKYO (JP) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145005-A1 | KINASE INHIBITOR | PIM3, PIM1, PIM2 | PDE4B 2887/4885USP30 2703/4885PDE4A 2929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.